Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 3/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL792960 | 0.80 | LTA4H (0.53) | LMNAMAPTRAB9ACYP1A2 | |
| SCHEMBL20177203 | 0.80 | KDM4E (0.40) | CYP2D6LMNARAB9ACYP1A2PKM | |
| Hydrochloric Acid SCHEMBL772237 | 0.79 | LTA4H (0.52) | LMNAMAPTRAB9ACYP1A2 | |
| SCHEMBL19257973 | 0.78 | RAD52 (0.46) | CYP3A4LMNARAB9A | |
| Hydrochloric Acid SCHEMBL20586638 | 0.77 | RAD52 (0.45) | CYP3A4LMNARAB9A | |
| Hydrochloric Acid SCHEMBL19209193 | 0.77 | RAD52 (0.45) | CYP3A4LMNARAB9A | |
| SCHEMBL4379883 | 0.76 | EPHX1 (0.44) | CYP2D6CYP1A2PKM | |
| SCHEMBL6685124 | 0.76 | EPHX1 (0.44) | CYP2D6CYP1A2PKM | |
| SCHEMBL8143963 | 0.76 | EPHX1 (0.44) | CYP2D6CYP1A2PKM | |
| Hydrochloric Acid SCHEMBL22691671 | 0.75 | EPHX1 (0.42) | CYP3A4CYP2D6CYP1A2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | PLA2G4A 4040/4885SLC2A1 4374/4885CYP3A4 1341/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | PLA2G4A 4040/4885SLC2A1 4374/4885CYP3A4 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.